but is not optimal in terms of efficacy or tolerability. Toll-like 7 receptor (TLR-7) agonists stimulate the innate immune system to produce, among other cytokines, IFN-␣ and are being evaluated as alternative drugs to treat HCV infection. This paper describes the application of pharmacokinetic-pharmacodynamic (PK-PD) modeling to understanding the behavior of a TLR-7 agonist [9-benzyl-8-hydroxy-2-(2-methoxyethoxy) adenine (BHMA)] in mice, using IFN-␣ as a biomarker. This is the first report of such a PK-PD model, and the conclusions may be of utility in the clinical development of TLR-7 agonists for HCV infection.
An estimated 200 million people worldwide (39) are infected with hepatitis c virus (HCV). The virus replicates primarily in the liver, and 70% of those infected go on to develop chronic infection, with a further 20% progressing to serious liver disease (6) . The current standard of care for HCV infection is treatment with pegylated alpha interferon (IFN-␣) combined with ribavirin; however, this treatment is effective for less than 50% of patients (26) . Furthermore, significant side effects, including flu-like symptoms, depression, injection site reactions, and hemolytic anemia, are observed (10) . The need to develop more available, better-tolerated, and more effective medicines is therefore clear. To this end, one of the areas of interest has been the targeting of IFN inducers (13, 18) and specifically Toll-like 7 receptor (TLR-7) agonists (9) . The TLR family plays a critical role in the innate immune response via recognition of pathogen-associated molecular patterns (PAMPs). These are conserved and essential to viability. TLR-7 itself is thought to be endosomally located and to recognize and bind single-stranded RNA. This results in the induction of type I IFN production, including a robust IFN-␣ response, leading in turn to an antiviral effect. This response has been described previously as recognizing abnormal localization of nucleic acid rather than structures or motifs absent from the host (reference 7; for a review, see also reference 8).
Although the hypothesis supporting the development of TLR-7 agonists as novel drugs appears to be sound, the behavior of a given drug in the in vivo system is often very hard to predict, leading to attrition due to lack of efficacy or safety concerns (20) . As a means to address this issue quantitatively, biomarker and translational pharmacology approaches (25) and modeling-and simulation-based drug development (22, 37) are being explored as ways forward. To develop an improved understanding of translational pharmacology, biomarkers of efficacy that are present both in preclinical species and in humans would be highly valuable. A number of potential biomarkers of relevance for HCV have been reported previously (see, e.g., references 1, 16, and 38). Of these biomarkers, IFN-␣ is attractive as it is readily measurable in preclinical species and humans by commercially available assays. In addition, basic mathematical descriptions relating dose levels of recombinant human IFN-␣ and viral loads in HCVinfected patients have been published (28) .
It has been shown previously that TLR-7 agonists have some antiviral activity in preclinical species, for example, toward influenza virus in rats (12) . Moreover, there are some data suggesting effects against HCV in humans (16, 24) . However, there are to date no tolerable TLR-7 agonist drug formulations that can be generally used to treat systemic viral infections such as HCV infection. One potential impediment to progress is the lack of understanding of the pharmacokinetic-pharmacodynamic (PK-PD) behavior of TLR-7 agonists in patients. The advantages of a PK-PD modeling approach include the ability to relate the PD effect to measures of primary pharmacology, the minimization of variables in extrapolation between species, and mechanistic insight (for reviews, see references 5 and 30). Hence, our aim was to generate appropriate data with mice and construct a PK-PD model describing these data for an example of a TLR-7 agonist, 9-benzyl-8-hydroxy-2-(2-methoxyethoxy) adenine (BHMA). The potential application of such an understanding of drug concentration and response in the clinical setting is discussed.
MATERIALS AND METHODS
Human replicon in vitro antiviral assay. The human replicon assay was carried out as described in reference 34; briefly, human hepatoma cells (Huh-7) with the persistent replicon PFKI389 Luc Ubi Neo NS3-3Ј/ET (ReBLikon GmbH) were used. The replicon cells were plated into tissue culture-grade white 96-well plates (PerkinElmer) at 10 4 cells/well in a volume of 90 l. Following TLR stimulation, 10 l of peripheral blood mononuclear cell supernatant was added to the HCV replicon cells, and the cells were incubated for 48 h. Replicon levels were quantified using a Promega Bright Glo luciferase detection kit according to the manufacturer's instructions.
Compounds. BHMA was synthesized as described elsewhere (21) . Unless stated otherwise, all other compounds were purchased from Sigma (Poole, United Kingdom).
In vivo experiments with BHMA. BHMA was orally administered to male cd-1 outbred mice (Charles River Laboratories UK, Margate, Kent, United Kingdom) in a vehicle of 5% dimethyl sulfoxide, 50% polyethylene glycol 200, and 45% water. For the PD groups, the following dose levels (with numbers of animals per group in parentheses) were used: 0.1 mg/kg of body weight (3), 0.3 mg/kg (2), 0.5 mg/kg (2), 1 mg/kg (10), 2.5 mg/kg (4), 5 mg/kg (20) , and 10 mg/kg (5) . At designated time points, two 50-l saphenous vein blood samples per animal were taken, and a terminal 1-ml blood sample was obtained. A matrix sampling system was employed to capture composite biomarker and PK profiles. For the PK-only groups, dose levels of 5, 1, and 0.1 mg/kg were used and plasma samples were taken at 0.1, 0.25, 1, 2, 6, 8, 10, and 24 h for the 5-mg/kg-dose group and at 1, 2, 6, 8, and 10 h for the 1-and 0.1-mg/kg-dose groups. In total, 25 animals were dosed and subjected to sampling for PK analysis. Plasma samples were prepared by centrifugation and stored at Ϫ20°C until analysis.
All animal studies were conducted according to the guidelines set by the United Kingdom Home Office Code of Practice for the Housing and Care of Animals Used in Scientific Procedures (1989) .
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of plasma samples for BHMA. All samples were analyzed for BHMA quantification by using a PE-Sciex API 4000 (Turbo V Ionspray source) quadrupole mass spectrometer. Samples (180 l) were injected with the use of a PAL autosampler (CTC Analytics, Zwingen, Switzerland) onto a C 18 Opti-Lynx 15-by 2.1-mm, 40-m-particle-size column (Optimize Technologies). The total run time was 2 min. Analytes were eluted using a linear ballistic gradient consisting of 10% methanol (MeOH), 90% H 2 O, 0.027% formic acid, and 2 mM ammonium acetate (solution A) and 90% MeOH, 10% H 2 O, 0.027% formic acid, and 2 mM ammonium acetate (solution B), produced by two Hewlett Packard HP1100 binary pumps. An initial condition of 0 to 100% solution A was maintained for 0.2 min, with the flow diverted to waste via a six-port valve (Valco International, Schenkon, Switzerland). This condition was then ramped up to an intermediate condition (0 to 100% solution B), and the flow was diverted through a Chromolith SpeedROD RP-18 50-by 4.6-mm column (Onyx Technologies) up to the 1.2-min time point. Filters (pore size, 5 m) were placed directly in front of the analytical column, between the column and the autosampler. The intermediate condition (0 to 100% solution B) was then held for 1.9 min and returned to the initial condition to reequilibrate the column. The total run time was 2 min. During the run, the flow was maintained at 3,000 l/min and split 5:1 postcolumn step by using an Acurate flow splitter. The calibration and quality control (QC) standards were prepared to yield a coefficient of variation (CV) of 20%. The limit of quantification (LOQ) in this analysis was 0.5 ng/ml.
Compound detection (bioanalysis of BHMA). Systemic plasma compound levels were assessed via a mixed-mode cationic solid-phase extraction procedure using an Oasis Elution MCX system. Plasma samples (50 l) were treated by the addition of 200 l of H 2 O-methanol (90:10, with 2% formic acid) containing an internal standard. The block was then preconditioned and equilibrated by drawing through 200 l of MeOH, followed by 200 l H 2 O (2% formic acid), under a vacuum. Pretreated plasma samples were then loaded and drawn through under a vacuum. Each well was subsequently washed by the addition of 200 l of H 2 O (2% formic acid), followed by 200 l of MeOH. All the samples were eluted into a 2-ml V-bottom 96-well block by drawing 50 l of MeOH (5% ammonia) through each well. Following this step, 200 l of an aqueous mobile phase (MeOH-H 2 O, 10:90) was used to reconstitute all samples. The block was then centrifuged for 30 min at 3,000 rpm and 4°C prior to injection onto the LC-MS/MS instrument.
Estimation of f u by equilibrium dialysis. Plasma binding free fractions (f u ) were determined using a proprietary, validated 96-well equilibrium dialysis method. Spectra 96-well equilibrium dialysis membranes (molecular mass cutoff, 12 to 14 kDa) were conditioned for 30 min in Dulbecco's phosphate-buffered saline (dPBS). The analyte was spiked to a concentration of 1 g/ml in preprepared male mouse plasma-brain homogenate, and 150-l aliquots (n ϭ 5) were loaded into the 96-well equilibrium dialysis apparatus. The samples were dialyzed against 150 l of dPBS for 4 h at 37°C in a CO 2 incubator in order to reach equilibrium. After 4 h, 50-l buffer and plasma aliquots were taken and added to a 2-ml 96-well polypropylene plate. Fifty microliters of control buffer was added to the plasma or control plasma was added to the buffer samples to give identical matrices for samples. The samples were then subjected to extraction by the Elution MCX solid-phase extraction method mentioned above and analyzed via LC-MS/MS. A calibration line from 5 to 1,200 ng/ml was constructed, and the CV for the repeat determination of the BHMA level was 20%. The mean f u was derived from five replicates.
Biomarker sample analysis (IFN levels). IFN-␣ assays were carried out using a modification of a commercially available kit (PBL Biomedical Laboratories Inc., Piscataway, NJ). Mouse plasma was diluted either 1:10 or 1:20 by using sample dilution buffer (PBL Biomedical Laboratories Inc., Piscataway, NJ). Standards were prepared from a 10-ng/ml working solution of mouse IFN-␣ (PBL Biomedical Laboratories Inc., Piscataway, NJ). Volumes of 100 l of the standard or the samples were added to the designated wells of 96-well microtiter plates, precoated with mouse IFN-␣ capture antibody (PBL Biomedical Laboratories Inc., Piscataway, NJ). The plates were incubated in a Tetramax 1000 shaker and incubator (Heidolph Instruments GmbH, Schwabach, Germany) at 25°C and 250 rpm for 2 h. The plates were washed once with 250 l of wash solution (PBL wash concentrate-deionized water [1:20] ) prechilled to 4°C and dispensed using a DELFIA plate washer (Wallac OY, Turku, Finland). Mouse IFN-␣ detection antibody (PBL Biomedical Laboratories Inc., Piscataway, NJ) was diluted 1:200 by using sample dilution buffer, and 100 l of the dilution was then added to each well. The wells were covered with film, incubated at 25°C, and shaken at 250 rpm for 24 h prior to being washed three times with wash buffer. Horseradish peroxidase (HRP) conjugate (PBL Biomedical Laboratories Inc., Piscataway, NJ) was diluted 1:300 by using HRP conjugate dilution buffer (PBL Biomedical Laboratories Inc., Piscataway, NJ), and 100 l of the preparation was added to each well. Plates were incubated at 25°C and 250 rpm for 2 h and then washed four times with wash buffer. One hundred microliters of tetramethylbenzidine substrate solution (PBL Biomedical Laboratories Inc., Piscataway, NJ) was added to each well. Plates were sealed with self-adhesive covers and incubated at 25°C and 100 rpm for 30 min. One hundred microliters of stop solution (PBL Biomedical Laboratories Inc., Piscataway, NJ) was added to each well, and the absorbance at 450 nm, with background subtraction at 650 nm, was measured using a Victor 2 multilabel counter (Wallac OY, Turku, Finland). The relationship between absorbance units and the mouse IFN-␣ concentration (in picograms per milliliter) was modeled using a five-parameter logistic fit. The sample IFN-␣ concentration was then derived by interpolation. Samples were assayed in duplicate, with five QC duplicates at each concentration level. The calculated concentration was then converted into international units per milliliter by assuming that 1 IU/ml equals 15 pg/ml. Plasma standards and QC standards were prepared identically to the corresponding samples with respect to the final composition.
The LOQ was 0.3 IU/ml, and the CV for the determination of the IFN-␣ concentration was 20%.
PK and PK-PD modeling. PK and PK-PD model analyses were carried out using NONMEM VI (Icon Consulting) with Compaq Visual Fortran, version 6.6. All data visualization was carried out using S-Plus (version 6.2). Murine PK was modeled using the ADVAN4 subroutine of NONMEM (two-compartmental PK), and the murine BHMA PK and PD for IFN induction and elimination were modeled using ADVAN6 for numerical solution of ordinary differential equations.
The IFN-␣ response to drug concentrations in plasma was modeled according to an indirect response model in which the response of the biomarker to the drug is caused by stimulation of the biomarker and the baseline response is zero (11) . In this model, IFN-␣ is synthesized in the presence of the drug with a sigmoid saturating concentration-response relationship and is degraded at a constant rate according to equation 1:
where dR/dt is the net rate of change in the IFN-␣ concentration (in international units per milliliter per hour), S max is the maximum rate of synthesis of IFN-␣ (in international units per milliliter per hour), SC 50 is the concentration of the compound (in nanograms per milliliter) required for half-maximal synthesis of IFN-␣, k out is the elimination rate constant for IFN-␣ (expressed as a value per hour), C p is the predicted plasma drug concentration (in nanograms per milliliter), and R is the plasma IFN-␣ concentration in international units per milliliter. The essential features of the model are summarized in Fig. 1 . Data were also modeled according to a linear drug response per equation 2:
where M is the linear slope of the response to the drug (in international units per milliliter per hour per nanogram per milliliter). Statistical parameters and population and individual predictions were calculated using the first-order conditional estimation method with interaction be-1180 BENSON ET AL. ANTIMICROB. AGENTS CHEMOTHER.
tween the two levels of stochastic effects (FOCE interaction), as implemented in NONMEM (3). Details of mixed-effects statistical analysis. The interindividual variability (IIV) of appropriate parameters was modeled using multiplicative exponential random effects as expressed in equation 3:
where is the typical population value for the parameter, P i is the individual prediction, and i is the random deviation of P i from . The values of i were assumed to be normally distributed, with a mean of zero and a variance of 2 . The derived IIV is expressed as the percent CV. The precision of parameter estimates was expressed as the percentage of the ratio of the standard error divided by the parameter estimate (percent CV).
Residual variability was described using additive and proportional error models (equations 4 and 5, respectively):
where Y ij denotes the observation for the i th individual at time t j , F ij denotes the corresponding prediction based on the model, and ε ij denotes the residual random effect assumed to have a mean of zero and a variance of 
RESULTS
PK of BHMA in mice. BHMA was rapidly absorbed following oral dosing, and after reaching a maximum concentration in plasma within 0.1 h, it showed some evidence of a biphasic decrease (Fig. 2) . By simultaneously fitting all the data, we found that the plasma PK for BHMA was best described by a two-compartment PK model with first-order uptake from the gastrointestinal tract and linear elimination (Table 1 and a Parameters were obtained by fitting data to a two-compartment PK model with first-order uptake and linear elimination. CL, clearance; V 2 , V in the central compartment; K a , absorption rate constant from compartment 1; Q, intercompartmental clearance between compartments 2 and 3; V 3 , V in the peripheral compartment.
b Fix, parameter fixed at the stated value.
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complete absorption prior to the collection of the earliest PK samples (at 0.1 h). In general, the PK was described well, with CVs for parameters between 16 and 36%. The IIV of the clearance was 38%, and the residual error was 46%. The f u in plasma was found to be 0.33 (standard error ϭ 0.006). PK and PD of IFN induction by BHMA in mice. Using the IFN-␣ assay, we found that in the absence of a TLR-7 agonist, the basal level of IFN-␣ was, in all cases, below the LOQ of our assay (0.3 IU/ml), and hence it was fixed at zero for the purpose of PK-PD modeling. Upon oral dosing with BHMA, a rapid and dose-dependent rise in the plasma IFN-␣ concentration was observed, with the concentration peaking at approximately 1 to 2 h around 300 IU/ml and decreasing rapidly back to zero. By using PK parameters for animals with corresponding PD parameters and elsewhere fixing the PK parameters at their typical population values, a sequential PK-PD analysis was performed using both an indirect ordinary maximum-effect (E max ) model (equation 1), in which the drug effect saturates, and a model in which induction was a linear function of the plasma drug concentration (equation 2). Using the AIC (equation 6) to calculate significance, we found that comparing the ordinary E max model with a linear model gave a ⌬AIC of Ϫ22.9 and that, therefore, the ordinary E max model had the superior fit. The indirect ordinary fit to the data was optimal with IIV implemented for the maximum synthesis rate of IFN (S max ), and all model parameters could be adequately identified, with CVs ranging from 0.1 to 24% ( Table 2) . IIV of the S max was high at 70%, and the residual error was 65 IU/ml ( Fig. 3 and Table 2 ). The typical SC 50 was 135 ng/ml total, which with correction for the free fraction equates to 125 nM.
Human replicon assay potency. The observed potency of BHMA in the human surrogate replicon assay of antiviral efficacy was ca. 30 nM.
DISCUSSION
Previously, it has been shown that TLR-7 agonists can elicit the release of antiviral cytokines in mice (21) . In this study, we extend this analysis to include application of PK-PD modeling, using BHMA as a standard TLR agonist and IFN-␣ as a biomarker of effect. This approach confers advantages in that the structure and parameters of the model can be related to prior mechanistic data, the concentration response can be related to any in vitro measures of pharmacology, and extrapolation of preclinical findings to the clinical outcome can in principle be facilitated. For example, a mechanistic PK-PD approach was used previously to show that buprenorphine-specific PD parameters such as binding of the drug to the target were similar in rats and humans (40) . In addition, it has been found that although concentration-response data can translate well between species, the dose response can be very different due to interspecies PK differences (23). Our intention was to define the concentration response in mice and to relate this to in vitro measures of pharmacology and to the existing knowledge of the behavior of TLR-7 agonists. Ultimately, this understanding could be used to improve confidence in the extrapolation of effects for patients and optimize clinical trial design.
The PK parameters of BHMA were estimated with good precision. However, without intravenous data, the bioavailability (F) cannot be estimated, and hence, the volume of distribution (V) of ca. 40 liters/kg must be regarded as the V/F ratio. The oral bioavailability of BHMA has been reported previously to be ϳ40% at 3 mg/kg in rats, and the V has been reported to be ca. 2.1 liters/kg (21) . Due to relatively similar tissue compositions in mice and rats, V tends to scale with an exponent close to 1 (19, 27) , and so the observed V at steady state (V ss ) in mice would appear to be high, given that the f u s in plasma for rats and mice are 0.22 and 0.33, respectively. However, bioavailability needs to be accounted for, and a low value of ca. 5% for this parameter in this case could explain the apparent discrepancy. The solubility of BHMA was found to be low (ca. 6 g/ml), and this may contribute to limited and dose-dependent bioavailability. Further data will be required to elucidate this point; nevertheless, the description of the data would appear to be adequate for the purpose of PK-PD modeling.
We found that the IFN-␣ data were better described by an indirect E max model than by a linear model. Arguably, a more complex model may be more appropriate; however, our analysis shows that the ordinary E max model is a reasonable description of the data without obvious bias. Such a model would also be consistent with the proposed mechanism of agonist action whereby saturable binding of a TLR-7 agonist to TLR-7 results in the synthesis and release of IFN-␣ (36) .
In general, the PK-PD model parameters were estimated with good precision, a notable exception being the S max . Conceivably, the variability may arise from residual measurement error, interindividual error, or a combination of these. Experiments to define the interexperimental variability of the assay methodology prior to use showed that the CV of quantification of IFN-␣ was 20% of the typical value. In addition, the model fit yielded reasonable estimates of residual variation and IIV. Taking these observations together, it would appear that most of the observed dispersion in the maximum response is more likely to be an interindividual PD difference, rather than being due to assay variability.
The model allowed the estimation of the midpoint of the concentration response, the degradation rate constant, and the maximum velocity of production of IFN-␣. The apparent degradation rate constant for IFN-␣ was 0.96 h Ϫ1 , giving a half-life (t 1/2 ) of approximately 0.7 h, and hence the majority of the induced IFN-␣ is cleared from the plasma in 3 to 4 h. The terminal half-life of IFN in mice has been reported previously to be ca. 50 min (29) (or given t 1/2 ϭ 0.693/k, then k ϭ 0.83 h Ϫ1 ), versus ca. 43 min determined in this study. Hence, the estimate of the IFN-␣ degradation rate would appear to be consistent with previous data. The typical maximum velocity of production of IFN-␣ was estimated to be 294 IU/ml/h, and the maximum response is given by the S max /k out ratio of 306 IU/ml. The maximum in vivo response, as measured using an antiviral bioassay, has been reported previously to be 2,872 IU of IFN/ml in BALB/c mice (21) . It is most likely that the apparent difference derives in large part from the difference between using the single biomarker IFN-␣ and the more general measure of multiple IFN types and potentially other mediators in the antiviral bioassay. This would be consistent with the documented spectrum of cytokines released by peripheral blood mononuclear cells upon challenge with TLR-7 agonists (2, 34). Interestingly, a survey of the available literature revealed that across a number of studies, a typical maximum response in humans (determined via antiviral bioassays) was ϳ10,000 IU of IFN/ml (17, 33, 38) , and therefore, maximum IFN responses appear not to be grossly different between mice and humans.
By correcting for the free fraction, the in vivo unbound SC 50 could be calculated. A future interesting direction for this work would be to develop assays of binding at the murine TLR-7 that would allow comparison of in vivo SC 50 and primary in vitro pharmacology measures. In turn, this should help improve understanding of the plasma and site-of-effect equilibriums. Interestingly, however, the SC 50 estimate was approximately fourfold our estimate of observed potency in the human surrogate replicon assay of antiviral efficacy (ca. 125 nM versus 30 nM). Whether this result reflects an expectation of good crossspecies translation and, indeed, whether the replicon surrogate assay is a good indicator of clinical outcome will become apparent as more clinical data for TLR-7 agonists become available.
The observed apparent burst in IFN-␣ raises some intriguing questions. The clear pharmacological effect implies rapid penetration of BHMA into appropriate cells, such as the plasmacytoid dendritic cells (PDCs), and the endosomes therein. The IFN-␣ levels then rapidly decay back to the baseline as the drug is cleared from the plasma. In contrast, it has been shown that infection of mice with DNA and RNA viruses leads to sustained IFN-␣ induction for at least up to 12 h and survival for up to 14 days (15) . Furthermore, it has also been found that TLR-9 ligands can be retained for long periods in the endosomal vesicles of PDCs and that this retention is critical to the robust response (14) . In this model, the retention of a TLR-7 agonist in the endosome is not required; however, further data are needed to demonstrate this conclusively. Conceivably, the retention profile could potentially be an important determinant of the time of response and may differ among TLR-7 agonists. For example, if it were possible to design drugs with endosomal retention, then this feature could confer effects independent of PK, similar to the effects of designing drugs with longer residence times on the receptor as discussed recently (35) ; such a parameter could be a selectable property of drug candidates.
The model implies also that repeat dosing with BHMA would result in replicate bursts of IFN-␣ release and, with the right dosing regimen, in sustained IFN-␣ as observed after infection with DNA and RNA viruses. However, as the model has been constructed using single-dose data only, such a conclusion would be an extrapolation, and hence repeat dose experiments with individuals are needed to test this assumption.
One further potential utility of measuring IFN-␣ and developing PK-PD models of IFN-␣ response to TLR-7 agonists in early clinical research may be to provide a quantitative link to outcome. Equations that describe the impact of recombinant IFN-␣ on viral load decrease have been reported previously (28, 31) . Hence, with a PK-PD model of the drug-dependent IFN-␣ time course in humans, a dose-antiviral response relationship could be calculated, assuming that recombinant IFN behaves similarly to the native form. The potential benefits of linking a biomarker of pharmacology (e.g., IFN-␣) to a biomarker of effect (viral load) in this way may include improved clinical trial design and more rapid and cost-effective delivery of medicines to patients. For example, this method provides a quantitative method to estimate a dose around which patient clinical trials could be designed. In addition, an understanding of variability may be crucial; we have shown that the IFN-␣ response to BHMA in mice appears to show quite large IIV, and patient responses to TLR-7 agonists have also been found to be inconsistent, for example, 370 to 23,000 U of IFN/ml in one dose group for imiquimod (38) . Furthermore, patient responses to recombinant IFN itself in the reduction of viral load have also been found to be variable (4) . Together, these data indicate that an understanding of the structure and population variability in IFN responses to TLR-7 agonists and the variability in the subsequent antiviral effects will be invaluable in the interpretation and extrapolation to patients of any data from IFN-␣ biomarker volunteer clinical trials (38) . PK-PD models incorporating both structural and stochastic elements as exemplified in this study will be a valuable tool to interpret such data, to inform the design of trials, and indeed, to project the likelihood of a successful outcome.
In summary, the PK-PD methods described in this report provide the basis to improve our understanding of the behavior of BHMA and potentially other TLR-7 agonists in vivo. Hence, identification of the features of a drug that are required for success can be facilitated. Furthermore, the findings should be of utility in the development of PK-PD models of IFN-␣ biomarker data for humans, and ultimately, such models could be used to provide a rational basis for the selection of optimal doses and schedules for antiviral agents.
